| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/27/2011 | US20110020455 Solid dispersion and pharmaceutical composition of the same, and production processes thereof |
| 01/27/2011 | US20110020454 Novel dosage and formulation |
| 01/27/2011 | US20110020453 Topical Formulations Comprising Ion Channel Modulators |
| 01/27/2011 | US20110020452 Progenitor cell replication and differentiation in 3d |
| 01/27/2011 | US20110020451 Tamper-resistant dosage form for oxidation-sensitive opioids |
| 01/27/2011 | US20110020450 Titratable dosage transdermal delivery system |
| 01/27/2011 | US20110020449 Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivatives |
| 01/27/2011 | US20110020448 Pharmaceutical composition for the treatment and prevention of glaucoma |
| 01/27/2011 | US20110020447 Novel dosage form |
| 01/27/2011 | US20110020446 Methods and formulations for making pharmaceutical compositions containing bupropion |
| 01/27/2011 | US20110020445 Extended release pharmaceutical compositions of levetiracetam |
| 01/27/2011 | US20110020444 Abuse-resistant opioid dosage form |
| 01/27/2011 | US20110020443 Slow release magnesium composition and uses thereof |
| 01/27/2011 | US20110020442 Taste Masked Oral Composition of Telithromycin |
| 01/27/2011 | US20110020441 Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis |
| 01/27/2011 | US20110020440 Stable solutions of sparingly soluble actives |
| 01/27/2011 | US20110020439 Delayed release compositions of duloxetine |
| 01/27/2011 | US20110020438 Crystallization Inhibitor and Its Use in Gelatin Capsules |
| 01/27/2011 | US20110020437 Oligopeptidic compounds and uses thereof |
| 01/27/2011 | US20110020436 Topical application of melatonin directly or in liposomes for the amelioration of itching and histamine and non-histamine related inflammatory skin changes |
| 01/27/2011 | US20110020435 Stabilizing alkylglycoside compositions and methods thereof |
| 01/27/2011 | US20110020434 Nanoparticle arsenic-platinum compositions |
| 01/27/2011 | US20110020433 Compositions for delivery of cargo such as drugs proteins and/or genetic materials |
| 01/27/2011 | US20110020432 Compositions and methods of use for post-radiation protection |
| 01/27/2011 | US20110020431 Antitumor effect of mutant bik |
| 01/27/2011 | US20110020430 Novel mRNA splice variant of the doublecortin-like kinase gene and its use in cancer diagnosis and therapy |
| 01/27/2011 | US20110020429 Use of particles comprising an alcohol |
| 01/27/2011 | US20110020428 Gel-stabilized liposome compositions, methods for their preparation and uses thereof |
| 01/27/2011 | US20110020427 Method Of Treating Malignant Solid Tumors Using Transcatheter Arterial Chemoembolization (TACE) |
| 01/27/2011 | US20110020426 Process for the continuous manufacture of a polyisobutylene based transdermal patch |
| 01/27/2011 | US20110020424 Use of the irritating principal oleocanthal in olive oil, as well as structurally and functionally similar compounds |
| 01/27/2011 | US20110020423 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| 01/27/2011 | US20110020420 Variable Density Tissue Graft Composition and Methods of Making and Using the Same |
| 01/27/2011 | US20110020412 Novel dosage and formulation |
| 01/27/2011 | US20110020411 Factor replacement therapy |
| 01/27/2011 | US20110020410 Stable solid preparations |
| 01/27/2011 | US20110020409 Silk Fibroin Hydrogels and Uses Thereof |
| 01/27/2011 | US20110020408 multilayered modified release formulation comprising amoxicillin and clavulanate |
| 01/27/2011 | US20110020407 Transdermal therapeutic system with high rate of utilization of active substance and dosing accuracy |
| 01/27/2011 | US20110020306 Probiotic, Lactic Acid-Producing Bacteria and Uses Thereof |
| 01/27/2011 | US20110020305 Probiotic, Lactic Acid-Producing Bacteria and Uses Thereof |
| 01/27/2011 | US20110020264 Method and Composition for the Treatment of Scars |
| 01/27/2011 | US20110020243 Methods and compositions for imaging cancer cells |
| 01/27/2011 | US20110020242 High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles |
| 01/27/2011 | US20110020236 Method for the synthesis of hollow spheres |
| 01/27/2011 | US20110020234 Rna interference mediating small rna molecules |
| 01/27/2011 | US20110020227 Polysaccharide-containing block copolmer particles and uses thereof |
| 01/27/2011 | US20110020226 Particle structures comprising sterols and saponins |
| 01/27/2011 | US20110020225 Porous polymer particles immobilized with charged molecules and method for preparing the same |
| 01/27/2011 | US20110020216 Scaffolds for cell collection or elimination |
| 01/27/2011 | DE102010027315A1 Verfahren zur Entwicklung einer als Schaum auf die Haut zu applizierende flüssige Zusammensetzung sowie eine topisch applizierbare Zusammensetzung A process for the development of a foam on the skin as a liquid composition to be applied, and a topically applicable composition |
| 01/27/2011 | DE102009027938A1 Oral dosage form, useful to administer active agent to human/animal and treat organism or its (patho)physiological conditions, comprises a base body with an opening, where the body contains an active agent formulation and blowing agent |
| 01/27/2011 | CA2804215A1 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| 01/27/2011 | CA2768810A1 Skin external-preparation composition |
| 01/27/2011 | CA2768656A1 Ferric citrate dosage forms |
| 01/27/2011 | CA2768646A1 Process for the continuous manufacture of a polyisobutylene based transdermal patch |
| 01/27/2011 | CA2768643A1 Differentiation of human embryonic stem cells |
| 01/27/2011 | CA2768471A1 Methods of attenuating the loss of functional status |
| 01/27/2011 | CA2768457A1 Pharmaceutical compositions |
| 01/27/2011 | CA2768024A1 A stable pharmaceutical omeprazole formulation for oral administration |
| 01/27/2011 | CA2767967A1 Multi-layered gradient vaginal ring |
| 01/27/2011 | CA2767888A1 Tamper-resistant dosage form for oxidation-sensitive opioids |
| 01/27/2011 | CA2766172A1 Oxidation-stabilized tamper-resistant dosage form |
| 01/27/2011 | CA2765971A1 Hot-melt extruded controlled release dosage form |
| 01/27/2011 | CA2761600A1 Fentanyl-containing adhesive preparation for external use |
| 01/27/2011 | CA2752849A1 Liquid compositions capable of foaming and including active agents, and methods for making or developing same |
| 01/26/2011 | EP2277594A2 Lysis / resealing process and device for incorporating an active ingredient in erythrocytes |
| 01/26/2011 | EP2277556A1 Two-phase, water-absorbent bioadhesive composition |
| 01/26/2011 | EP2277549A2 Therapeutic polyanhydride compounds for drug delivery |
| 01/26/2011 | EP2277548A2 Magnetic nanoparticles linked to a ligand |
| 01/26/2011 | EP2277545A1 Particle with inducible shape alteration |
| 01/26/2011 | EP2277544A1 Biocompatible magnetic nano-clusters containing iron oxide respectively iron oxide - boron with primary use in magnetic drug targeting and boron neutron capture therapy |
| 01/26/2011 | EP2277540A2 Polyanionic polymer adjuvants for haemophilus influenza B saccharide vaccines |
| 01/26/2011 | EP2277521A1 Tamper-resitant oral opioid agonist formulations |
| 01/26/2011 | EP2277518A1 Use of silymarin and silybin in the treatment of neural injury |
| 01/26/2011 | EP2277517A1 Nateglinide tablet composition |
| 01/26/2011 | EP2277514A1 A method for chemoprevention of prostate cancer |
| 01/26/2011 | EP2277512A2 Pharmaceutical compositions and dosage forms of thalidomide |
| 01/26/2011 | EP2277511A1 Extended release pharmaceutical compositions of levetiracetam |
| 01/26/2011 | EP2277510A2 Controlled release preparation |
| 01/26/2011 | EP2277509A1 DPP IV inhibitor formulations |
| 01/26/2011 | EP2277508A1 Emulation of lipoprotein structures |
| 01/26/2011 | EP2277507A1 Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| 01/26/2011 | EP2277506A1 Non-polar buccal spray of a sedative |
| 01/26/2011 | EP2277505A2 Mucoactive agents for treating a pulmonary disease |
| 01/26/2011 | EP2277504A1 Substituted tetracycline compounds for the treatment of malaria |
| 01/26/2011 | EP2277503A1 Effervescent compositions comprising bisphosphonates and methods related thereto |
| 01/26/2011 | EP2277388A1 Solid alpechin product and process for preparing a solid alpechin product |
| 01/26/2011 | EP2276727A1 Methods and compositions comprising novel cationic lipids |
| 01/26/2011 | EP2276504A1 Vascular aging inhibitor and anti-aging formulation |
| 01/26/2011 | EP2276494A1 Stable aqueous compositions comprising bioactive creatine species |
| 01/26/2011 | EP2276477A2 Self-destructing transdermal therapeutic system having improved functionality and efficacy |
| 01/26/2011 | EP2276476A1 Manufacturing method of thermo-rod for active drug release the thermo-rod |
| 01/26/2011 | EP2276475A1 Biodegradable nanoshells for delivery of therapeutic and/or imaging molecules |
| 01/26/2011 | EP2276474A1 Solid oral form with dual release profile, containing multiparticulates |
| 01/26/2011 | EP2276473A1 Carbidopa/lipodopa gastroretentive drug delivery |
| 01/26/2011 | EP2276472A1 Compositions comprising weakly basic drugs and controlled-release dosage forms |
| 01/26/2011 | EP2276471A2 Composite lacrimal insert and related methods |
| 01/26/2011 | EP2276470A2 Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
| 01/26/2011 | EP2276469A2 Alpha adrenergic receptor agonists for treatment of degenerative disc disease |